NanoMosaic alliance positions Solid Biosciences Inc. to advance precision AAV capsid research

NanoMosaic alliance positions Solid Biosciences Inc. to advance precision AAV capsid research
Solid and NanoMosaic join forces

Solid Biosciences Inc. has entered into a co-marketing agreement with NanoMosaic, aiming to drive forward the development of next generation gene therapies.

The partnership focuses on unlocking the full potential of adeno-associated virus (AAV) technology, leveraging innovative capsid design approaches such as Solid Biosciences Inc.'s proprietary POLARIS-101 platform. Both companies intend to combine their expertise to support rapid advancements in precision genetic medicines.

Solid Biosciences recently presented clinical insights into its SGT-003 gene therapy candidate for Duchenne muscular dystrophy at a leading scientific congress, according to a prior company update. The company is also slated to participate in the upcoming Jefferies Global Healthcare Conference, where CEO Bo Cumbo will lead a fireside chat on June 3, as noted in a recent announcement. These events contribute to Solid Biosciences' continued engagement with the gene therapy sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.